Status:

COMPLETED

The Significance of Postoperative Muscle Wasting in Pancreatic Cancer

Lead Sponsor:

National Cheng-Kung University Hospital

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

20-120 years

Brief Summary

To assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.

Detailed Description

Previous studies have revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, is a poor prognostic factor following surgery. However, research focusing on postoperative muscle w...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of pancreatic cancer
  • Must be able to undergo pancreatectomy
  • Must be able to undergo pre- and post-operative abdominal computed tomography scan

Exclusion

  • Unresectable pancreatic cancer

Key Trial Info

Start Date :

June 1 2002

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2023

Estimated Enrollment :

208 Patients enrolled

Trial Details

Trial ID

NCT06093009

Start Date

June 1 2002

End Date

June 1 2023

Last Update

October 24 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Cheng Kung University Hospital

Tainan, Taiwan

The Significance of Postoperative Muscle Wasting in Pancreatic Cancer | DecenTrialz